US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.
News
Sanofi, Regeneron’s Dupixent shines in rhinosinusitis with nasal polyps trials
Sanofi and Regeneron have unveiled top-line data showing that two late-stage studies of Dupixent in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps met all their primary and secondary endpoints.
Amgen begins rolling out Humira biosimilar in the EU
Amgen has begun launching Amgevita, the first biosimilar of AbbVie’s anti-inflammatory blockbuster Humira to win approval in Europe, across the region.
NHS Trafford CCG placing team of pharmacists in care homes
NHS Trafford Clinical Commissioning Group is placing a team of pharmacists to work across care homes in the borough to boost access to healthcare in the community.
PureTech affiliate Karuna advances schizophrenia candidate
Karuna Pharmaceuticals, an affiliate of UK-listed biopharma PureTech Health, has kicked off a Phase II study of KarXT, which is being developed for the treatment of psychosis in schizophrenia.
Roche’s Kadcyla shows promise in early breast cancer
Roche has announced that its antibody drug conjugate Kadcyla cut the risk of disease recurrence when given after neoadjuvant treatment and surgery to certain breast cancer patients with residual disease.
England falling behind peers on child health
The Royal College of Paediatrics and Child Health (RCPCH) is calling for a properly funded, long-term plan to transform the life chances of young people, after finding that England is in danger of falling further behind its peers on child health.
Santhera’s cystic fibrosis drug POL6014 in line for orphan status
Santhera says its experimental cystic fibrosis drug POL6014 is likely to be designated an orphan drug in the next 30 days, putting the firm in line to receive regulatory and financial incentives for its further development.
Opdivo fails to hit key target in small cell lung cancer study
Bristol-Myers Squibb’s immunotherapy Opdivo did not hit the primary target of a late-stage study testing its efficacy in certain patients with small cell lung cancer.
Immugenyx and Janssen to develop humanised mouse model of lupus
UK biopharma Hemogenyx Pharmaceuticals has signed a deal with Janssen Research & Development to create a humanised mouse model of lupus.
UK doctors allowed to prescribe medical cannabis from November
From November 1 specialist clinicians in the UK will be able to prescribe cannabis-derived medicinal products for the first time after a change in the law, the Home Office has confirmed.
Xarelto approved to cut risk of major CV events in CAD/PAD patients
US regulators have approved Bayer/Janssen’s Xarelto to cut the risk of major cardiovascular (CV) events in people with chronic coronary or peripheral artery disease (CAD/PAD).
New competition celebrates excellence in medical information
Medical information professionals are being invited to test their mettle at this year’s inaugural PharmaTimes Medical & Scientific Excellence Awards, established to showcase and reward excellence in the field.
EU validates Rigel marketing application for fostamatinib
European regulators have validated Rigel Pharmaceuticals’ application to market fostamatinib for adult chronic immune thrombocytopenia (ITP).
Carrick licenses targeted ovarian cancer drug from BTG
Dublin, Ireland-based biopharma Carrick Therapeutics has licensed exclusive globl rights to develop and commercialise BTG’s targeted ovarian cancer drug BTG945.
